These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 33496278)

  • 21. Cost-benefit analysis: newborn screening for inborn errors of metabolism in Lebanon.
    Khneisser I; Adib S; Assaad S; Megarbane A; Karam P
    J Med Screen; 2015 Dec; 22(4):182-6. PubMed ID: 26062758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Specific guidelines for assessing and improving the methodological quality of economic evaluations of newborn screening.
    Langer A; Holle R; John J
    BMC Health Serv Res; 2012 Sep; 12():300. PubMed ID: 22947299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic evaluation of tandem mass spectrometry screening in California.
    Feuchtbaum L; Cunningham G
    Pediatrics; 2006 May; 117(5 Pt 2):S280-6. PubMed ID: 16735254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The cost-effectiveness of expanding newborn screening for up to 21 inherited metabolic disorders using tandem mass spectrometry: results from a decision-analytic model.
    Cipriano LE; Rupar CA; Zaric GS
    Value Health; 2007; 10(2):83-97. PubMed ID: 17391418
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ethics, evidence, and cost in newborn screening.
    Baily MA; Murray TH
    Hastings Cent Rep; 2008; 38(3):23-31. PubMed ID: 18581934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Newborn screening for congenital heart defects: a systematic review and cost-effectiveness analysis.
    Knowles R; Griebsch I; Dezateux C; Brown J; Bull C; Wren C
    Health Technol Assess; 2005 Nov; 9(44):1-152, iii-iv. PubMed ID: 16297355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of newborn screening for severe combined immunodeficiency.
    Van der Ploeg CPB; Blom M; Bredius RGM; van der Burg M; Schielen PCJI; Verkerk PH; Van den Akker-van Marle ME
    Eur J Pediatr; 2019 May; 178(5):721-729. PubMed ID: 30805731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economics of tandem mass spectrometry screening of neonatal inherited disorders.
    Pandor A; Eastham J; Chilcott J; Paisley S; Beverley C
    Int J Technol Assess Health Care; 2006; 22(3):321-6. PubMed ID: 16984060
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic evaluation of tandem mass spectrometry newborn screening in Australia.
    Norman R; Haas M; Chaplin M; Joy P; Wilcken B
    Pediatrics; 2009 Feb; 123(2):451-7. PubMed ID: 19171609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Strategies for newborn screening for cystic fibrosis: A systematic review of health economic evaluations.
    Schmidt M; Werbrouck A; Verhaeghe N; De Wachter E; Simoens S; Annemans L; Putman K
    J Cyst Fibros; 2018 May; 17(3):306-315. PubMed ID: 29572018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Financing state newborn screening programs: sources and uses of funds.
    Johnson K; Lloyd-Puryear MA; Mann MY; Ramos LR; Therrell BL
    Pediatrics; 2006 May; 117(5 Pt 2):S270-9. PubMed ID: 16735253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness analysis of neonatal screening of critical congenital heart defects in China.
    Tobe RG; Martin GR; Li F; Moriichi A; Wu B; Mori R
    Medicine (Baltimore); 2017 Nov; 96(46):e8683. PubMed ID: 29145300
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The neonatal screening programs in Spain.Science, research and public health, keys to their quality and effectiveness.].
    Dulín Iñiguez E; Eguileor Gurtubai I; Espada Sáenz-Torre M
    Rev Esp Salud Publica; 2021 Jan; 95():. PubMed ID: 33496275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The cost-effectiveness of neonatal versus prenatal screening for congenital toxoplasmosis.
    Binquet C; Lejeune C; Seror V; Peyron F; Bertaux AC; Scemama O; Quantin C; Béjean S; Stillwaggon E; Wallon M
    PLoS One; 2019; 14(9):e0221709. PubMed ID: 31532766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Newborn screening: current status.
    Arn PH
    Health Aff (Millwood); 2007; 26(2):559-66. PubMed ID: 17339686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Newborn hearing screening: the great omission.
    Mehl AL; Thomson V
    Pediatrics; 1998 Jan; 101(1):E4. PubMed ID: 9417168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expanded newborn screening for genetic and metabolic disorders: modeling costs and outcomes.
    Hubbard HB
    Nurs Econ; 2007; 25(6):345-52. PubMed ID: 18240836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of Universal and Targeted Newborn Screening for Congenital Cytomegalovirus Infection.
    Gantt S; Dionne F; Kozak FK; Goshen O; Goldfarb DM; Park AH; Boppana SB; Fowler K
    JAMA Pediatr; 2016 Dec; 170(12):1173-1180. PubMed ID: 27723885
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic evaluation of the breast cancer screening programme in the Basque Country: retrospective cost-effectiveness and budget impact analysis.
    Arrospide A; Rue M; van Ravesteyn NT; Comas M; Soto-Gordoa M; Sarriugarte G; Mar J
    BMC Cancer; 2016 Jun; 16():344. PubMed ID: 27251556
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.